Gravity Analytica

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

KALV 11.04.2024

SERA-AI Powered Highlights

Drug:sebetralstat-HAE sebetralstat

Diseases:hereditary angioedema

Full Press Release SEC Filings Our KALV Tweets

About Gravity Analytica

Recent Filings

–Provides up to$184 millioninvestment to support commercial launch of sebetralstat which, if approved, will be the first and only oral on-demand therapy for HAE –

–Strengthens financial position asKalVistaestablishes global footprint for expected launches in multiple geographies in 2025–

CAMBRIDGE, Mass.&SALISBURY, England--(BUSINESS WIRE)--Nov. 4, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to$179 million, comprised of a$100 millionupfront payment, a one-time$22 millionoptional payment uponU.S.product approval, and up to$57 millionin a sales-based milestone payment. The proceeds of this transaction will be used to fund the commercialization of sebetralstat, which, if approved, is expected to be the first approved oral on-demand therapy to treat hereditary angioedema (“HAE”).KalVistahas a New Drug Application for sebetralstat under review by theU.S. Food and Drug Administration(the “FDA”) with a Prescription Drug User Free Act (“PDUFA”) target action date ofJune 17, 2025.

DRI has also indicated an interest in investing up to$5 millionin KalVista’s common stock in a private placement transaction. However, this indication of interest is not binding agreement or commitment to purchase KalVista’s common stock and DRI may decide to purchase more, less or no shares of KalVista’s common stock andKalVistamay decide to not sell shares of its common stock to DRI.

“This financing arrangement is a pivotal step forKalVista, enabling us to continue building a global commercial organization ahead of the potentialU.S.launch of sebetralstat in June 2025,” saidBen Palleiko, Chief Executive Officer ofKalVista. “Moving forward, we are well-positioned to achieve long-term sustainable growth as we focus on delivering a potentially transformative treatment for people living with HAE. We appreciate DRI’s confidence inKalVistaand sebetralstat to make this their first pre-approval investment.”

“Our royalty investment reflects DRI’s research-driven belief that sebetralstat has the potential to be the foundational treatment for all people living with HAE. We are excited to support theKalVistateam’s continued transformation toward a commercial organization at this important stage,” saidNavin Jacob, Chief Investment Officer of DRI.

“Acquiring a synthetic royalty on such a high-quality asset like sebetralstat showcases DRI’s willingness to develop partnerships with companies likeKalVistawho are seeking to meaningfully improve patients’ lives,” saidAli Hedayat, Acting Chief Executive Officer of DRI.

Synthetic Royalty Financing Terms

Under the terms of the synthetic royalty financing agreement,KalVistawill immediately receive$100 millionand be obligated to pay DRI a tiered royalty of 5.00% of annual global net sales up to and including$500 million, 1.10% of annual global net sales above$500 millionand up to and including$750 million, and 0.25% of annual global net sales above$750 million.KalVistais entitled to a potential one-time sales-based milestone payment of$50 millionif annual global net sales of sebetralstat meet or exceed$550 millionin any calendar year beforeJanuary 1, 2031.

If sebetralstat is approved prior toOctober 1, 2025,KalVistawill have the option to receive a one-time payment of$22 million. IfKalVistachooses to receive this optional payment, the royalty rate on net sales up to and including$500 millionwill increase from 5.00% to 6.00%, and the sales-based milestone amount will increase from$50 millionto$57 million.

Jefferies LLCacted as exclusive financial advisor toKalVistaon the synthetic royalty financing.

About Sebetralstat

Discovered and developed entirely by the scientific team atKalVista, sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE. Sebetralstat received Fast Track and Orphan Drug Designations from the FDA, as well as Orphan Drug Designation and an approved Pediatric Investigational Plan from theEuropean Medicines Agency(“EMA”).

About Hereditary Angioedema

HAE is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (“C1INH”) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the location affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration.

AboutKalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet need. Sebetralstat, KalVista’s novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date ofJune 17, 2025. In addition,KalVistahas completed marketing authorization application (“MAA”) submissions for sebetralstat to the EMA as well as regulatory authorities in theUnited Kingdom,Switzerland,Australia, andSingapore, andKalVistaanticipates filing a MAA inJapanin late 2024.

For more information aboutKalVista, please visitwww.kalvista.comor follow on social media at@KalVistaandLinkedIn.

About DRI Healthcare Trust

DRI is managed byDRI Capital Inc.(“DRI Healthcare”), a pioneer in global pharmaceutical royalty monetization. Since its initial public offering in 2021, the Trust has deployed more thanUS$1.0 billion, acquiring more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. DRI’s units are listed and trade on theToronto Stock Exchangein Canadian dollars under the symbol “DHT.UN” and inU.S.dollars under the symbol “DHT.U”. To learn more, visitdrihealthcare.comor follow DRI onLinkedIn.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of theU.S.Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from whatKalVistaexpects. Examples of forward-looking statements include, among others, the potential and timing of royalty payments, the potential timing of an equity investment in KalVista’s common stock, expectations regarding KalVista’s regulatory submissions, the anticipated royalty income and anticipated sales of products underlying such royalties, timing or outcomes of communications with the FDA, the success of any efforts to commercialize sebetralstat, and the ability of sebetralstat and other candidates in development to treat HAE or other diseases. Further information on potential risk factors that could affect KalVista’s business and financial results are detailed in its filings with theSecurities and Exchange Commission, including in its annual report on Form 10-K for the year endedApril 30, 2024, its quarterly reports on Form 10-Q, and its other reports thatKalVistamay make from time to time with theSecurities and Exchange Commission.KalVistaundertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241104880996/en/

Jenn SnyderVice President, Corporate Affairs(617) 448-0281jsnyder@kalvista.com

Ryan BakerHead, Investor Relations(617) 771-5001ryan.baker@kalvista.com

Source:KalVista Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com